Skip to Main Content


The term cyclic antidepressant (CA) refers to a group of pharmacologically related xenobiotics used for treatment of depression, neuralgic pain, migraines, enuresis, and attention deficit hyperactivity disorder. Most CAs have at least three rings in their chemical structure. They include the traditional tricyclic antidepressants (TCAs) imipramine, desipramine, amitriptyline, nortriptyline, doxepin, trimipramine, protriptyline, and clomipramine, as well as other cyclic compounds such as maprotiline and amoxapine.


Imipramine was the first TCA used for treatment of depression in the late 1950s. However, the synthesis of iminodibenzyl, the "tricyclic" core of imipramine, and the description of its chemical characteristics date back to 1889. Structurally related to the phenothiazines, imipramine was originally developed as a hypnotic agent for agitated or psychotic patients and was serendipitously found to alleviate depression. From the 1960s until the late 1980s, the TCAs were the major pharmacologic treatment for depression in the United States. However, by the early 1960s, cardiovascular and central nervous system (CNS) toxicities were recognized as major complications of TCA overdoses.99 The newer CAs developed in the 1980s and 1990s were designed to decrease some of the adverse effects of older TCAs, improve the therapeutic index, and reduce the incidence of serious toxicity. Other CAs include the tetracyclic drug maprotiline and the dibenzoxapine drug amoxapine.


The epidemiology of CA poisoning has evolved significantly in the last 20 years, resulting in great part from the introduction of the newer selective serotonin reuptake inhibitors (SSRIs) for the treatment of depression. Although the use of CAs for depression has decreased over the last 15 years, other medical indications, including chronic pain, obsessive-compulsive disorder, and, particularly in children, enuresis and attention deficit hyperactivity disorder have emerged, resulting in their continued use. The antidepressants are a leading cause of drug-related self-poisonings in the developed world, primarily because of their ready availability to people with depression who by virtue of the disease are at high risk for overdose. However, despite the increase in SSRI use and overdose, patients with TCA overdoses continue to have higher rates of hospitalization (78.7% versus 64.7%) and fatality (0.73% versus 0.14%) than do those with SSRI overdose.73


Children younger than 6 years have consistently accounted for approximately 12%–13% of all CA exposures reported to poison centers during each of the last 15 years (see Chap. 135). Despite the emergence of the SSRIs in the early 1990s, TCAs were still among the top five psychotropic drugs most frequently prescribed by pediatric office—based practices in 1995.48 The use of TCAs has remained stable in adolescents but has declined in prepubertal children.116 Thus CA poisoning likely will continue to be among the most lethal unintentional drug ingestions in younger children because only one or two adult-strength pills can produce serious clinical effects in young children.


In general, the TCAs can be classified into tertiary and secondary amines based on the presence of a methyl group on the propylamine side chain ...

Want remote access to your institution's subscription?

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.


About MyAccess

If your institution subscribes to this resource, and you don't have a MyAccess profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.

Subscription Options

AccessEmergency Medicine Full Site: One-Year Subscription

Connect to the full suite of AccessEmergency Medicine content and resources including advanced 8th edition chapters of Tintinalli’s, high-quality procedural videos and images, interactive board review, an integrated drug database, and more.

$595 USD
Buy Now

Pay Per View: Timed Access to all of AccessEmergency Medicine

24 Hour Subscription $34.95

Buy Now

48 Hour Subscription $54.95

Buy Now

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.